News | March 06, 2024
Bayer aims to enhance performance and regain strategic flexibility by 2026
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
This agreement paves the way for the introduction of YESAFILI into the Canadian market
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Subscribe To Our Newsletter & Stay Updated
